CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The EBOVAC program aims to evaluate a new vaccine regimen against Ebola Virus Disease through extensive clinical trials in Europe and Africa. It focuses on assessing safety and effectiveness, with parallel trials to expedite the development process.
The overall aim of the EBOVAC programme is to assess the safety and efficacy of a novel prime boost prophylactic vaccine regimen against Ebola Virus Disease (EVD), which has been 100% effective in preclinical studies.
This will be done via phase I, II and III trials carried out in the EU and in Africa, in response to the urgent public health need raised by the current Ebola epidemic.
To expedite the development of the vaccine regimen, Phase II and Phase III trials will be carried out in parallel…
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Janssen Vaccines (f.k.a. Crucell Holland B.V.)
Netherlands, Leiden
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
United Kingdom, Oxford
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Bordeaux
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
